EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

BACKGROUND: In the Phase III LUX-Lung 3/6 (LL3/LL6) trials in epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma patients, we evaluated feasibility of EGFR mutation detection using circulating cell-free DNA (cfDNA) and prognostic and predictive utility of cfDNA positivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Long, Sequist, Lecia V, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Li, Wei, Hou, Mei, Schuler, Martin, Mok, Tony, Yamamoto, Nobuyuki, O'Byrne, Kenneth, Hirsh, Vera, Gibson, Neil, Massey, Dan, Kim, Miyoung, Yang, James Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243999/
https://www.ncbi.nlm.nih.gov/pubmed/28006816
http://dx.doi.org/10.1038/bjc.2016.420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243999/
https://www.ncbi.nlm.nih.gov/pubmed/28006816
http://dx.doi.org/10.1038/bjc.2016.420

Ejemplares similares